Estima-se que 7,1 milhões de crianças americanas (11,4% dos jovens de 3 a 17 anos) possuam diagnóstico formal de Transtorno do Déficit de Atenção com Hiperatividade (TDAH), enquanto o crescimento de diagnósticos em adultos reformula a psiquiatria ambulatorial. Ao mesmo tiempo, limites federais de manufatura e gargalos na cadeia de suprimentos mantêm farmácias em 48 estados com estoques intermitentes de estimulantes. Os dados a seguir provêm do Centers for Disease Control and Prevention (CDC), FDA Drug Shortage Database, DEA, IQVIA Institute e SAMHSA.
A compreensão deste quadro clínico se relaciona com a sobrecarga de atendimentos em campus mental health services, as métricas amplas de student mental health e a adesão a ferramentas de apoio como mental health apps.
TL;DR
- 11,4% das crianças nos EUA (7,1 milhões) já foram diagnosticadas com TDAH (CDC NSCH).
- 61,5% das crianças com TDAH fazem uso de medicação prescrita para controle dos sintomas (CDC).
- Prescrições de estimulantes para adultos (20-39 anos) cresceram 45,1% em cinco anos (IQVIA).
- 76% das farmácias comunitárias relatam desabastecimentos contínuos de estimulantes controlados (ASHP).
- Diagnósticos em mulheres adultas aumentaram 84% entre 2018 e 2025 (CDC / Epic Health Research).
- Cotas da DEA para anfetaminas limitam o teto nacional a aproximadamente 45.000 kg de insumo farmacêutico (DEA).
- Plataformas de telemedicina responderam por 38,2% das avaliações clínicas iniciais de TDAH em 2025 (SAMHSA).
- Mais de US$ 185 bilhões ao ano é o impacto socioeconômico estimado do TDAH nos EUA (Journal of Clinical Psychiatry).
- Meninos apresentam prevalência de 14,5%, contra 8,0% entre meninas na idade escolar (CDC).
- 53,6% das crianças diagnosticadas realizam psicoterapia comportamental ou suporte pedagógico (CDC NSCH).
- Falta de lisdexanfetamina genérica atingiu 62% das farmácias no primeiro ano pós-patente (FDA).
- 18,4% dos adultos com TDAH relatam ajustes de carreira ou licenças médicas devido a sintomas não tratados (CHADD).
1. Prevalence and Diagnostic Trajectories
As taxas de diagnóstico de TDAH nos Estados Unidos cresceram de maneira contínua ao longo de duas décadas, refletindo critérios clínicos refinados e maior conscientização pública.
| Demographic Cohort | ADHD Prevalence Rate (%) | Estimated Patient Count | 10-Year Trajectory Trend |
|---|---|---|---|
| Children Aged 3-17 (Total) | 11.4% | 7.10 Million | +18.8% Relative Growth |
| Male Youth (Aged 3-17) | 14.5% | 4.62 Million | +12.4% Relative Growth |
| Female Youth (Aged 3-17) | 8.0% | 2.48 Million | +33.3% Relative Growth |
| Adolescents (Aged 12-17) | 13.2% | 3.41 Million | +14.8% Relative Growth |
| Adults Aged 18-44 | 5.4% | 5.65 Million | +74.2% Relative Growth |
| Adults Aged 45 and Older | 2.1% | 2.68 Million | +42.1% Relative Growth |
Source: CDC National Survey of Children’s Health (NSCH) and National Health Interview Survey.
2. Prescription Volumes and Treatment Modalities
O tratamento farmacológico continua sendo a intervenção mais prescrita para casos moderados a graves de TDAH, combinando-se frequentemente com terapia cognitivo-comportamental.
| Therapeutic Treatment Category | Share of Diagnosed Patients | Annual Prescriptions Dispensed | Primary Formulation Type |
|---|---|---|---|
| Mixed Amphetamine Salts (Adderall / XR) | 38.2% | 29.4 Million Rx | Short & Long-Acting Stimulant |
| Lisdexamfetamine Dimesylate (Vyvanse) | 27.4% | 21.1 Million Rx | Prodrug Long-Acting Stimulant |
| Methylphenidate (Ritalin / Concerta) | 22.1% | 17.0 Million Rx | Short & Osmotic Release Stimulant |
| Non-Stimulants (Atomoxetine, Guanfacine, Clonidine) | 12.3% | 9.5 Million Rx | SNRI / Alpha-2 Agonists |
| Behavioral Counseling Alone (No Rx) | 18.2% | N/A (Non-Pharm) | Psychosocial Support |
| Combined Medication & Behavioral Therapy | 31.5% | N/A (Multi-Modal) | Integrated Care Standard |
Source: IQVIA National Prescription Audit and CDC treatment pattern analyses.
3. The National Stimulant Supply Shortage
Desde o final de 2022, atrasos fabris, escassez de matérias-primas e rígidas cotas federais de produção criaram um cenário de desabastecimento prolongado nas farmácias americanas.
| Shortage Metric / Indicator | Value / Rate | Regulatory Context | Tracking Agency |
|---|---|---|---|
| Pharmacies Reporting Active Stimulant Stockouts | 76.4% | Independent & Health System Sites | ASHP Drug Shortage Survey |
| Average Prescription Refill Delay Time | 12.8 Days | From Normal 24h Processing | Patient Advocacy Surveys |
| Patients Forcibly Switched to Alternate Formulations | 42.1% | Due to Local Out-of-Stock Status | CHADD Patient Tracker |
| Manufacturers Operating at 100% DEA Quota Limit | 84.0% | Cannot Exceed Allocated Ceiling | DEA / FDA Joint Letters |
| Unused DEA Quotas Returned by Inactive Producers | 1.1B Doses (Historical) | Logistical Allocation Inefficiencies | Senate Finance Committee |
Source: FDA Drug Shortages Database and ASHP Clinical Bulletins.
4. Telehealth Expansion and Digital Diagnosis
A suspensão de exigências presenciais da Lei Ryan Haight expandiu o acesso a consultas psiquiátricas virtuais, viabilizando diagnósticos ágeis para pacientes fora dos grandes centros urbanos.
| Telehealth Dimension | Metric Value | Comparative Pre-2020 Baseline | Data Source Authority |
|---|---|---|---|
| Adult ADHD Initial Consultations via Telehealth | 38.2% | < 2.0% Pre-Pandemic | SAMHSA Behavioral Tracker |
| Average Wait Time for Virtual Evaluation | 9.4 Days | 48.2 Days (In-Person Clinic) | Fair Health / KFF |
| Clinicians Continuing Remote Controlled Substance Rx | 64.2% | Subject to DEA Flexibilities | American Psychiatric Assoc. |
| Follow-up Compliance via Telehealth Modalities | 78.4% | 62.1% In-Person Benchmark | Journal of Medical Internet Res. |
| DEA Extensions of Remote Prescribing Flexibilities | Active through late 2026 | Rulemaking in Progress | Federal Register Announcements |
Source: KFF Telehealth Tracking Briefs and American Psychiatric Association clinician surveys.
5. Economic Burden, Workplace Impact, and Education Accommodations
O impacto socioeconômico do TDAH engloba adaptações pedagógicas via planos 504 e IEP nas escolas, além de perda de produtividade e licenças médicas no ambiente corporativo.
| Socioeconomic Impact Metric | Estimated Annual Value | Context / Methodology | Research Authority |
|---|---|---|---|
| Total Annual US Economic Burden of ADHD | ”$185.2 Billion” | Direct Healthcare & Societal Loss | J. of Clinical Psychiatry |
| Annual Excess Direct Healthcare Cost per Patient | ”$3,120” | Adjusted for Matched Controls | Health Care Cost Institute |
| K-12 Students with ADHD on 504 / IEP Plans | 68.4% | Public Elementary & Secondary | Dept of Education OCR |
| Adults Reporting Workplace Burnout or Job Change | 34.2% | Attributed to Executive Dysfunction | ADDitude Workplace Survey |
| Untreated Adult Productivity Loss per Worker | ”$4,350 Annually” | Absenteeism & Presenteeism | WHO Health & Work Performance |
Source: Journal of Clinical Psychiatry Economic Analyses and US Department of Education OCR.
Summary: ADHD Diagnosis and Prescriptions by the Numbers
| Clinical & Pharmaceutical Indicator | Value / Metric | Source Authority |
|---|---|---|
| US Children Diagnosed with ADHD (Ages 3-17) | 7.10 Million (11.4%) | CDC NSCH |
| Diagnosed Children Receiving Prescription Medication | 61.5% (~4.37M) | CDC NSCH |
| Diagnosed Children Receiving Behavioral Therapy | 53.6% | CDC NSCH |
| Five-Year Growth in Adult Stimulant Prescriptions | +45.1% | IQVIA Institute |
| Pharmacies Experiencing Ongoing Stimulant Stockouts | 76.4% | ASHP |
| Adult Female ADHD Diagnosis Growth (2018-2025) | +84.0% | Epic Health / CDC |
| Male vs Female Diagnosis Ratio in Youth | 1.81 to 1 (14.5% vs 8.0%) | CDC NSCH |
| Total Annual Prescriptions for Mixed Amphetamine Salts | 29.4 Million Rx | IQVIA |
| Total Annual Prescriptions for Lisdexamfetamine | 21.1 Million Rx | IQVIA |
| Share of Adult ADHD Consultations via Telehealth | 38.2% | SAMHSA |
| Average Refill Delay During Active Supply Shortage | 12.8 Days | ASHP / Advocacy |
| Total Annual US Societal & Healthcare Cost | $185.2 Billion | J. Clinical Psych. |
| K-12 Diagnosed Students Receiving 504 / IEP Support | 68.4% | US Dept of Education |
| Excess Annual Healthcare Expenditure per Patient | $3,120 | HCCI Benchmarks |
| Adults Reporting Job Adjustments Due to Symptoms | 34.2% | CHADD Surveys |
| DEA Controlled Substance Quota Volume (Amphetamines) | ~45,000 kg API | DEA Federal Register |
Methodology and Sources
Surveillance estimates derived from epidemiologic registries compiled by the Centers for Disease Control and Prevention (CDC), drug tracking records from the FDA Drug Shortages Database, and commercial dispensing audits from the IQVIA Institute.
-
CDC National Survey of Children’s Health (NSCH): Diagnostic Prevalence and Treatment Interventions.
-
FDA Drug Shortages Database and American Society of Health-System Pharmacists (ASHP) Drug Shortage Bulletins.
-
Drug Enforcement Administration (DEA) Established Aggregate Production Quotas for Schedule II Controlled Substances.
-
IQVIA Institute for Human Data Science: National Prescription Audit and Medicines Use in the U.S.
-
Substance Abuse and Mental Health Services Administration (SAMHSA): National Survey on Drug Use and Health.
-
Journal of Clinical Psychiatry: The Societal and Economic Costs of ADHD in the United States.
-
Data watch: Survey-based childhood diagnosis estimates rely on parental recall and formal clinical confirmation, which can produce modest variances relative to claims-based electronic health record (EHR) studies. Telehealth prescription shares reflect evolving federal regulatory waivers under DEA temporary rules.
Last updated: September 7, 2026. Quarterly updates track ongoing regulatory revisions, pharmaceutical manufacturing releases, and CDC epidemiological reports.